
Scandion Oncology Q3 2023 - Intriguing CORIST part 2 data

Redeye comments on Scandion Oncology's Q3 2023 report, one day after the company announced intriguing final data from CORIST part 2. Final CORIST part 2 data indicated elongated survival versus cited historical controls. We believe reported data is promising. However, they require confirmation in a controlled randomised trial. We do some housekeeping in our model and finetune our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scandion Oncology Q3 2023 - Intriguing CORIST part 2 data](#)